Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289727 | 0.86 | SMN1; SMN2 (0.48) | KMT2ASMN1; SMN2 | |
| SCHEMBL838971 | 0.79 | SLC6A9 (0.41) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL840848 | 0.76 | DPP4 (0.40) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL839785 | 0.76 | DPP4 (0.46) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL840944 | 0.74 | TRPM8 (0.46) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL839780 | 0.74 | SLC6A9 (0.42) | SLC6A9 | |
| SCHEMBL859083 | 0.74 | TRPM8 (0.46) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL30376859 | 0.73 | OPRD1 (0.60) | OPRD1SIGMAR1KCNH2HRH3DPP4 | |
| SCHEMBL839041 | 0.71 | SLC6A9 (0.38) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL2038120 | 0.71 | EPHX2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-8324217-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324217-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-05-31 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| EP-2331499-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | OPRD1 71/4885KMT2A 1721/4885SMN1; SMN2 2862/4885 |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | TRPV1, TRPM2, TRPM6 | OPRD1 71/4885KMT2A 1721/4885SMN1; SMN2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.